(Q417915)

SUFENTANIL (English)

3 October 2016

C₂₂H₃₀N₂O₂S

1 reference

SUFENTANIL (English)

19 November 2016

CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC

1 reference

European Medicines Agency product number

SUFENTANIL (English)

19 November 2016

1 reference

EMEA/H/C/002784

reference URL

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002784/human_med_001916.jsp

World Health Organisation international non-proprietary name

22 March 2017

sufentanil (English)

1 reference

sufentanil (English)

medical condition treated

3 October 2016

1 reference

significant drug interaction

13 December 2016

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fentanyl

1 reference

A reference set of clinically relevant adverse drug-drug interactions

remifentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alfentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pethidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pethidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(R,R)-tramadol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(R,R)-tramadol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

morphine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

morphine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

oxycodone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

oxycodone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hydromorphone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

hydromorphone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dihydrocodeine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dihydrocodeine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

codeine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

codeine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tapentadol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tapentadol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fentanyl

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fentanyl

1 reference

A reference set of clinically relevant adverse drug-drug interactions

remifentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

remifentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpheniramine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

periciazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alfentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alfentanil

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-promethazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-promethazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-promethazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

olanzapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

olanzapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

olanzapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

loxapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

loxapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

loxapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clozapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clozapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clozapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

itraconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

posaconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

voriconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ritonavir

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cobicistat

1 reference

A reference set of clinically relevant adverse drug-drug interactions

idelalisib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Ketoconazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levomepromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

levomepromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

trimeprazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

trimeprazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nitrazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nitrazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zopiclone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zopiclone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clobazam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clobazam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dexmedetomidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dexmedetomidine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

perampanel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

perampanel

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-thiopental

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(±)-thiopental

1 reference

A reference set of clinically relevant adverse drug-drug interactions

midazolam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

midazolam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-baclofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-baclofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

diazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

oxazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

oxazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

droperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

droperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zolpidem

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zolpidem

1 reference

A reference set of clinically relevant adverse drug-drug interactions

flurazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

flurazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aripiprazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aripiprazole

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

quetiapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

quetiapine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sodium oxybate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sodium oxybate

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alprazolam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alprazolam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

lorazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

lorazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clonazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clonazepam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlordiazepoxide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlordiazepoxide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenobarbital

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenobarbital

1 reference

A reference set of clinically relevant adverse drug-drug interactions

primidone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

primidone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

3534

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

17 August 2016

legal status (medicine)

boxed warning

1 reference

reference URL

imported from Wikimedia project

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

US pregnancy category C

1 reference

0 references

opioid receptor agonist

1 reference

5 March 2018

1 reference

15 March 2018

1 reference

15 March 2018

1 reference

MeSH descriptor ID

D017409

15 March 2018

intravenous anesthetics

1 reference

Institute for Safe Medication Practices

15 March 2018

SUFentanil

1 reference

reference URL

https://www.ismp.org/recommendations/tall-man-letters-list

InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3

2 September 2022

Commons category

Sufentanil

0 references

Identifiers

InChI

1 reference

GGCSSNBKKAUURC-UHFFFAOYSA-N

SUFENTANIL (English)

19 November 2016

2 references

SUFENTANIL (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

56030-54-7

2 references

GGCSSNBKKAUURC-UHFFFAOYSA-N

sufentanil (English)

19 November 2016

8 April 2021

https://commonchemistry.cas.org/detail?cas_rn=56030-54-7

1 reference

Sufentanil (English)

19 November 2016

1 reference

SUFENTANIL (English)

19 November 2016

Reaxys registry number

499558

1 reference

sufentanil (English)

3 October 2016

mapping relation type

1 reference

SUFENTANIL (English)

19 November 2016

1 reference

MSBNK-Univ_Connecticut-CO000421

SUFENTANIL (English)

19 November 2016

1 reference

MassBank accession ID

0 references

MSBNK-Univ_Connecticut-CO000422

0 references

MSBNK-Univ_Connecticut-CO000423

0 references

MSBNK-Univ_Connecticut-CO000424

0 references

MSBNK-Univ_Connecticut-CO000425

0 references

MSBNK-Waters-WA000640

0 references

MSBNK-Waters-WA000641

0 references

MSBNK-Waters-WA000642

0 references

MSBNK-Waters-WA000643

0 references

MSBNK-Waters-WA000644

0 references

SPLASH

splash10-000i-0096000000-73641c83c08b872641cd

0 references

splash10-06ri-1981000000-b5f4aaab095cc6fc533c

0 references

splash10-03di-1900000000-2fdfd1d5fa6e43fa1604

0 references

splash10-03di-4900000000-bd92c052347dc0822a01

0 references

HSDB ID

6760

1 reference

Hazardous Substances Data Bank

28 October 2019

Sufentanil (English)

10 May 2021

1 reference

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

DTXCID103604

0 references

EC number

641-081-8

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.168.858

27 December 2018

ECHA Substance Infocard ID

N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide (English)

quotation

CAS no.: 56030-54-7 (English)

100.168.858

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.168.858

27 December 2018

N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide (English)

quotation

CAS no.: 56030-54-7 (English)

1 reference

Guide to Pharmacology Ligand ID

Sufentanil (English)

publication date

17 November 2015

3534

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

3534

sufentanil (English)

19 November 2016

Sufentanil

0 references

0 references

0 references

1 reference

sufentanil (English)

19 November 2016

1 reference

Sufentanil (English)

Human Metabolome Database ID

19 November 2016

HMDB0014846

1 reference

based on heuristic

inferred from InChIKey

1 reference

sufentanil (English)

PatientsLikeMe treatment ID

19 November 2016

0 references

1 reference

sufentanil (English)

19 November 2016

0 references

1 reference

1 reference

sufentanil (English)

3 October 2016

1 reference

Immune Epitope Database and Analysis Resource

sufentanil (English)

3 October 2016

1 reference

1 March 2022

0 references

Encyclopedia of China (Second Edition) ID

141504

subject named as

舒芬太尼

0 references

Encyclopedia of China (Third Edition) ID

141504

subject named as

舒芬太尼

0 references

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

UMLS CUI

C0143993

1 reference